Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexJagath R. Junutula, William Mallet, Helga Raab et al.|Nature Biotechnology|2008Cited by 1.4k
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen‐Quan Shen, Jagath R. Junutula, Keyang Xu et al.|Nature Biotechnology|2012Cited by 997
Identification of Heregulin, a Specific Activator of p185 <sup>erbB2</sup>William E. Holmes, Richard Vandlen, Mark X. Sliwkowski et al.|Science|1992Cited by 964
IL-17E, a Novel Proinflammatory Ligand for the IL-17 Receptor Homolog IL-17Rh1James Lee, Austin Gurney, Wei-Hsien Ho et al.|Journal of Biological Chemistry|2001Cited by 410
Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug SelectionAndrew G. Polson, Allen Ebens, Jill Calemine-Fenaux et al.|Cancer Research|2009Cited by 248